Insider Selling: Illumina, Inc. (ILMN) SVP Sells 1,609 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) SVP Charles Dadswell sold 1,609 shares of the business’s stock in a transaction that occurred on Wednesday, May 3rd. The stock was sold at an average price of $187.07, for a total transaction of $300,995.63. Following the sale, the senior vice president now directly owns 10,936 shares in the company, valued at approximately $2,045,797.52. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Charles Dadswell also recently made the following trade(s):

  • On Monday, February 6th, Charles Dadswell sold 572 shares of Illumina stock. The shares were sold at an average price of $161.26, for a total transaction of $92,240.72.

Shares of Illumina, Inc. (NASDAQ:ILMN) traded up 0.64% during midday trading on Friday, hitting $177.01. 1,061,794 shares of the company were exchanged. The stock has a market capitalization of $25.84 billion, a price-to-earnings ratio of 35.82 and a beta of 0.79. The company has a 50-day moving average price of $178.52 and a 200-day moving average price of $156.83. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $189.48.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.64. The firm had revenue of $598 million during the quarter, compared to analysts’ expectations of $590.51 million. Illumina had a return on equity of 22.89% and a net margin of 19.31%. Illumina’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.71 EPS. On average, analysts forecast that Illumina, Inc. will post $3.63 EPS for the current year.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Illumina, Inc. (ILMN) SVP Sells 1,609 Shares of Stock” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/05/20/illumina-inc-ilmn-svp-sells-300995-63-in-stock-updated.html.

Several research firms recently issued reports on ILMN. BTIG Research reiterated a “hold” rating on shares of Illumina in a research note on Sunday, March 19th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $191.00 target price for the company in a research note on Tuesday, April 4th. Vetr cut shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $193.40 target price for the company. in a research note on Tuesday, April 11th. Bank of America Corp boosted their target price on shares of Illumina from $175.00 to $195.00 and gave the company a “buy” rating in a research note on Tuesday, April 11th. Finally, Leerink Swann boosted their target price on shares of Illumina from $134.00 to $138.00 and gave the company a “market perform” rating in a research note on Thursday, February 9th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Illumina presently has an average rating of “Hold” and a consensus price target of $164.97.

A number of institutional investors have recently added to or reduced their stakes in the company. Forte Capital LLC ADV boosted its position in Illumina by 1.6% in the first quarter. Forte Capital LLC ADV now owns 2,185 shares of the life sciences company’s stock worth $373,000 after buying an additional 35 shares in the last quarter. Gemmer Asset Management LLC boosted its position in Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock worth $117,000 after buying an additional 37 shares in the last quarter. Bronfman E.L. Rothschild L.P. boosted its position in Illumina by 3.6% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 1,198 shares of the life sciences company’s stock worth $204,000 after buying an additional 42 shares in the last quarter. Cleararc Capital Inc. boosted its position in Illumina by 1.3% in the first quarter. Cleararc Capital Inc. now owns 3,326 shares of the life sciences company’s stock worth $568,000 after buying an additional 44 shares in the last quarter. Finally, Concert Wealth Management Inc. boosted its position in Illumina by 2.9% in the third quarter. Concert Wealth Management Inc. now owns 1,732 shares of the life sciences company’s stock worth $315,000 after buying an additional 48 shares in the last quarter. Hedge funds and other institutional investors own 92.79% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

12 Month Chart for NASDAQ:ILMN

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply